Prochlorperazine sublingual - Benuvia Therapeutics
Alternative Names: Prochlorperazine - Benuvia TherapeuticsLatest Information Update: 28 Apr 2025
At a glance
- Originator Benuvia Therapeutics
- Class Antiemetics; Antipsychotics; Phenothiazines; Piperazines; Small molecules
- Mechanism of Action Dopamine D2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Nausea and vomiting; Psychotic disorders
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for research development in Nausea and vomiting in USA (Sublingual)
- 28 Apr 2025 No recent reports of development identified for research development in Psychotic-disorders in USA (Sublingual)
- 23 Mar 2021 Prochlorperazine sublingual is available for licensing as of 23 Mar 2021. https://www.benuvia.com/